Is cognitive functioning impaired in methamphetamine users? A critical review

Neuropsychopharmacology

Volumn 37, Issue 3, 2012, Pages 586-608

  Hart, Carl L ^a,b   Marvin, Caroline B ^a   Silver, Rae ^a,c   Smith, Edward E ^a,d  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c Barnard College of Columbia University   (United States)

^d NONE   (United States)

Author keywords

amphetamines; cognition; impairment; methamphetamine

Indexed keywords

METHAMPHETAMINE; RECREATIONAL DRUG;

ATTENTION; COGNITIVE DEFECT; DRUG ABUSE; HUMAN; LEARNING; LONG TERM MEMORY; NEUROIMAGING; PERCEPTION; PRIORITY JOURNAL; REVIEW; WORKING MEMORY;

AMPHETAMINE-RELATED DISORDERS; ATTENTION; COGNITION; COGNITION DISORDERS; HUMANS; MEMORY, LONG-TERM; METHAMPHETAMINE;

EID: 84855906407     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.276     Document Type: Review

References (88)

1. ADA Division of Communications; Journal of the American Dental Association; ADA Division of Scientific Affairs (2005). For the dental patient... methamphetamine use and oral health. Journal of the American Dental Association 136:1491.
2. Bartholow M (2010). Top 200 prescription drugs of 2009. Pharmacy Times www.pharmacytimes.com/publications/issue/2010/May2010/RxFocusTopDrugs-0510, accessed 12 July 2011.
3. Blakeslee S (2004). This is your brain on meth: a 'forest fire' of damage. The New York Times.
4. Belcher AM, Feinstein EM, O'Dell SJ, Marshall JF (2008). Methamphetamine influences on recognition memory: comparison of escalating and single-day dosing regimes. Neuropsychopharmacology 33:1453-1463. (Pubitemid 351521718)
5. Berman SM, Voytek B, Mandelkern MA, Hassid BD, Isaacson A, Monterosso J et al (2008). Changes in cerebral glucose metabolism during early abstinence from chronic methamphetamine abuse. Mol Psychiatry 13:897-908.
6. Boileau I, Rusjan P, Houle S, Wilkins D, Tong J, Selby P et al (2008). Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? J Neurosci 28:9850-9856.
7. Boone KB, Ghaffarian S, Lesser IM, Hill-Gutierrez E, Berman NG (1993). Wisconsin card sorting test performance in healthy, older adults: relationship to age, sex, education, and IQ. J Clin Psychol 49:54-60. (Pubitemid 23060005)
8. Cadet JL, Krasnova IN (2009). Molecular bases of methamphetamine-induced neurodegeneration. Int Rev Neurobiol 88:101-119.
9. Chang L, Cloak C, Patterson K, Grob C, Miller EN, Ernst T (2005). Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response. Biol Psychiatry 57:967-974. (Pubitemid 40603079)
10. Chang L, Ernst T, Speck O, Patel H, DeSilva M, Leonido-Yee M et al (2002). Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users. Psychiatry Res 114:65-79. (Pubitemid 34556681)
11. Cho AK, Melega WP, Kuczenski R, Segal DS (2001). Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 39:161-166. (Pubitemid 32104021)
12. Chung A, Lyoo IK, Kim SJ, Hwang J, Bae SC, Sung YH et al (2007). Decreased frontal white-matter integrity in abstinent methamphetamine abusers. Int J Neuropsychopharmacol 10:765-775. (Pubitemid 350035821)
13. Comer SD, Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW (2001). Effects of repeated oral methamphetamine administration in humans. Psychopharmacology 155:397-404. (Pubitemid 32523110)
14. Cretzmeyer M, Walker J, Hall JA, Arndt S (2007). Methamphetamine use and dental disease: results of a pilot study. J Dent Children 74:85-92.
15. Dobkin C, Nicosia N (2009). The war on drugs: methamphetamine, public health, and crime. Am Econ Rev 99:324-349.
16. Fleckenstein AE, Voltz TJ, Riddle EL, Gibb JW, Hanson GR (2007). New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47:681-698.
17. Gerasimov MR, Franceschi M, Volkow ND, Gifford A, Gatley SJ, Marsteller D et al (2000). Comparison between intraperitoneal and oral methylphenidate administration: a microdialysis and locomotor activity study. J Pharmacol Exp Therap 295:51-57.
18. Grelotti DJ, Kanayama G, Pope Jr HG (2010). Remission of persistent methamphetamine-induced psychosis after electroconvulsive therapy: presentation of a case and review of the literature. Am J Psychiatry 167:17-23.
19. Hamamoto DT, Rhodus NL (2009). Methamphetamine abuse and dentistry. Oral Dis 15:27-37.
20. Han DH, Yoon SJ, Sung YH, Lee YS, Kee BS, Lyoo IK et al (2008). A preliminary study: novelty seeking, frontal executive function, and dopamine receptor (D2) Taql A gene polymorphism in patients with methamphetamine dependence. Compreh Psychiatry 49:387-392.
21. Hart CL, Gunderson EW, Perez A, Kirkpatrick MG, Thurmond A, Comer SD et al (2008). Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology 33:1847-1855. (Pubitemid 351832594)
22. Hart CL, Haney M, Foltin RW, Fischman MW (2002). Effects of the NMDA antagonist memantine on human methamphetamine discrimination. Psychopharmacology 164:376-384. (Pubitemid 35435713)
23. Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW (2001). Methamphetamine self-administration by humans. Psychopharmacology 157:75-81. (Pubitemid 32758962)
24. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G (1993). Wisconsin Card Sorting Test Manual-Revised and Expanded. Psychological Assessment Resource: Lutz, FL.
25. Henry JD, Mazur M, Rendell PG (2009). Social-cognitive difficulties in former users of methamphetamine. Br J Clin Psychol 48:323-327.
26. Ho EL, Josephson SA, Lee HS, Smith WS (2009). Cerebrovascular complications of methamphetamine abuse. Neurocrit Care 10:295-305.
27. Hoffman WF, Moore M, Templin R, McFarland B, Hitzemann RJ, Mitchell SH (2006). Neuropsychological function and delay discounting in methamphetamine-dependent individuals. Psychopharmacology 188:162-170. (Pubitemid 44371154)
28. Hoffman WF, Schwartz DL, Huckans MS, McFarland BH, Meiri G, Stevens AA et al (2008). Cortical activation during delay discounting in abstinent methamphetamine dependent individuals. Psychopharmacology 201:183-193.
29. Hyman SE, Malenka RC, Nestler EJ (2006). Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 29:565-598. (Pubitemid 44476856)
30. Johanson CE, Frey KA, Lundahl LH, Keenan P, Lockhart N, Roll J et al (2006). Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology 185:327-338.
31. Johnson BA, Ait-Daoud N, Wells LT (2000). Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on D-methamphetamine-induced cognitive and physiological changes in humans. Neuropsychopharmacology 22:504-512. (Pubitemid 30145618)
32. Johnson BA, Roache JD, Ait-Daoud N, Wallace C, Wells LT, Wang Y (2005). Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition. Psychopharmacology 178:296-302. (Pubitemid 40379224)
33. Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Wallace CL, Dawes MA et al (2007). Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetaminedependent individuals. Prog Neuropsychopharmacol Biol Psychiatry 3:123-130. (Pubitemid 44959260)
34. Kalechstein AD, Newton TF, Green M (2003). Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci 15:215-220. (Pubitemid 36520342)
35. Kim SJ, Lyoo IK, Hwang J, Chung A, Hoon Sung Y, Kim J et al (2006). Prefrontal grey-matter changes in short-term and longterm abstinent methamphetamine abusers. Int J Neuropsychopharmacol 9:221-228. (Pubitemid 43255836)
36. Kim SJ, Lyoo IK, Hwang J, Sung YH, Lee HY, Lee DS et al (2005). Frontal glucose hypometabolism in abstinent methamphetamine users. Neuropsychopharmacology 30:1383-1391. (Pubitemid 40848092)
37. Kim YT, Lee SW, Kwon DH, Seo JH, Ahn BC, Lee J (2009). Dosedependent frontal hypometabolism on FDG-PET in methamphetamine abusers. J Psychiatric Res 43:1166-1170.
38. Kirkpatrick MG, Gunderson EW, Johanson CE, Levin FR, Foltin RW, Hart CL (in press a). Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans. Addiction.
39. Kirkpatrick MG, Gunderson EW, Perez AY, Haney M, Foltin RW, Hart CL (in press b). A direct comparison of the behavioral and physiological effects of methamphetamine and 3, 4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology; e-pub ahead of print 12 July 2011.
40. Kirkpatrick MG, Metcalfe J, Greene MJ, Hart CL (2008). Effects of intranasal methamphetamine on metacognition of agency. Psychopharmacology 197:137-144.
41. Lee B, London ED, Poldrack RA, Farahi J, Nacca A, Monterosso JR et al (2009). Striatal dopamine D2/D3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci 29:14734-14740.
42. Leland D, Arce E, Miller D, Paulus M (2008). Anterior cingulate cortex and benefit of predictive cueing on response inhibition in stimulant dependent individuals. Biol Psychiatry 63:184-190. (Pubitemid 350299327)
43. London ED, Berman SM, Voytek B, Simon SL, Mandelkern MA, Monterosso J et al (2005). Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. Biol Psychiatry 58:770-778. (Pubitemid 41677415)
44. London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J et al (2004). Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 61:73-84. (Pubitemid 38044643)
45. Marrone GF, Pardo J, Krauss RM, Hart CL (2010). Amphetamine analogs methamphetamine and 3, 4-methylenedioxymethamphetamine (MDMA) differentially affect speech. Psychopharmacology 208:169-177.
46. Marshall JF, Belcher AM, Feinstein EM, O'Dell SJ (2007). Methamphetamine-induced neural and cognitive changes in rodents. Addiction 102 (Suppl): 61-69. (Pubitemid 46328218)
47. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971). Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. J Clin Pharmacol Therap 12:245-258.
48. McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J et al (2008). Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 62:91-100.
49. 11C]WIN-35428. J Neurosci 18:8417-8422. (Pubitemid 28465016)
50. Mitrushina M, Boone KB, Razani J, D'Elia LF (2005). Handbook of Normative Data for Neuropsychological Assessment, 2nd edn. Oxford University Press: New York, NY.
51. Mohs RC, Tinklenberg JR, Roth WT, Kopell BS (1978). Methamphetamine and diphenhydramine effects on the rate of cognitive processing. Psychopharmacology 59:13-19. (Pubitemid 9013399)
52. Mohs RC, Tinklenberg JR, Roth WT, Kopell BS (1980). Sensitivity of some human cognitive functions to effects of methamphetamine and secobarbital. Drug Alcohol Depend 5:145-150. (Pubitemid 10159613)
53. Monterosso JR, Ainslie G, Xu J, Cordova X, Domier CP, London ED (2007). Frontoparietal cortical activity of methamphetaminedependent and comparison subjects performing a delay discounting task. Hum Brain Mapp 28:383-393. (Pubitemid 46717363)
54. Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz Y et al (2009). Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neutrons. Neuron 62:218-229.
55. O'Neil ML, Kuczenski R, Segal DS, Cho AK, Lacan G, Melega WP (2006). Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge. Synapse 60:465-473. (Pubitemid 44380158)
56. Paulus MP, Hozack N, Frank L, Brown GG, Schuckit MA (2003). Decision making by methamphetamine-dependent subjects is associated with error-rate-independent decrease in prefrontal and parietal activation. Biol Psychiatry 53:65-74. (Pubitemid 36050937)
57. Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, Braff DL et al (2002). Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects. Neuropsychopharmacology 26:53-63. (Pubitemid 34075276)
58. Payer DE, Lieberman MD, Monterosso JR, Xu J, Fong TW, London ED (2008). Differences in cortical activity between methamphetamine-dependent and healthy individuals performing a facial affect matching task. Drug Alcohol Depend 93:93-102. (Pubitemid 350236596)
59. Pilley C, Perngparn U (1998). Introduction to drug use and treatments in Thailand. J Demogr Vol 14:69-85.
60. Raiteri M, Cerrito F, Cervoni AM, Levi G (1979). Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J Pharmacol Exp Therap 208:195-202. (Pubitemid 9191708)
61. Rendell PG, Mazur M, Henry JD (2009). Prospective memory impairment in former users of methamphetamine. Psychopharmacology 203:609-616.
62. Rush CR, Stoops WW, Lile JA, Glaser PE, Hays LR (2011). Subjective and physiological effects of acute intranasal methamphetamine during D-amphetamine maintenance. Psychopharmacology 214:665-674.
63. Salo R, Nordahl TE, Buonocore MH, Natsuaki Y, Waters C, Moore CD et al (2009a). Cognitive control and white matter callosal microstructure in methamphetamine-dependent ubjects: a diffusion tensor imaging study. Biol Psychiatry 65:122-128.
64. Salo R, Ursu S, Buonocore MH, Leamon MH, Carter C (2009b). Impaired prefrontal cortical function and disrupted adaptive cognitive control in methamphetamine abusers: a functional magnetic resonance imaging study. Biol Psychiatry 65:706-709.
65. 2 receptors. J Neurosci 22:8002-8009. (Pubitemid 35379105)
66. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton JH, Grant I (2007). Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 17:275-297. (Pubitemid 47498174)
67. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK (2003). Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 28:1730-1740. (Pubitemid 41070838)
68. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H et al (2001). Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206-1214. (Pubitemid 32717692)
69. Sevak RJ, Stoops WW, Hays LR, Rush CR (2009). Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans. J Pharmacol Exp Ther 28:1007-1018.
70. Shetty V, Mooney LJ, Zigler CM, Belin TR, Murphy D, Rawson RJ (2010). The relationship between methamphetamine use and increased dental disease. J Am Dent Assoc 141:307-318.
71. Shohamy D, Myers CE, Kalanithi J, Gluck MA (2008). Basal ganglia and dopamine contributions to probabilistic category learning. Neurosci Biobehav Rev 32:219-236.
72. Silber BY, Croft RJ, Papafotiou K, Stough C (2006). The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance. Psychopharmacology 187:154-169. (Pubitemid 44015610)
73. Simon SL, Dean AC, Cordova X, Monterosso JR, London ED (2010). Methamphetamine dependence and neuropsychological functioning: evaluating change during early abstinence. J Stud Alcohol Drugs 71:335-344.
74. Simon SL, Domier C, Carnell J, Brethen P, Rawson R, Ling W (2000). Cognitive impairment in individuals currently using methamphetamine. Am J Addict 9:222-231.
75. Simon SL, Richardson K, Dacey J, Glynn S, Domier CP, Rawson RA et al (2002). A comparison of patterns of methamphetamine and cocaine use. J Addict Dis 21:35-44. (Pubitemid 35203852)
76. Sonders MS, Zhu S, Zahniser NR, Kavanaugh MP, Amara SG (1997). Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J Neurosci 17:960-974. (Pubitemid 27043955)
77. Sitte HH, Huck S, Reither H, Boehm S, Singer EA, Pifl C (1998). Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. J Neurochem 71:1289-1297. (Pubitemid 28390284)
78. Sulzer D, Sonders MS, Poulsen NW, Galli A (2005). Mechanisms of neurotransmitter release by amphetamines: a review. Progr Neurobiol 75:406-433. (Pubitemid 40834286)
79. Talland GA, Quarton GC (1965). The effects of methamphetamine and pentobarbital on the running memory span. Psychopharmacologia 7:379-382.
80. Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y et al (2004). Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 24:6028-6036. (Pubitemid 38859399)
81. UN Global ATS Assessment (2008). Amphetamines and ecstasy. United Nations Office of Drug and Crime.
82. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler MJ et al (2001a). Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am J Psychiatry 158:383-389. (Pubitemid 32205194)
83. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D et al (2001b). Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377-382. (Pubitemid 32205193)
84. Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M et al (2001c). Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 158:2015-2021. (Pubitemid 33104107)
85. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M et al (2001d). Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21:9414-9418. (Pubitemid 33096884)
86. Wang GJ, Volkow ND, Chang L, Miller E, Sedler M, Hitzemann R et al (2004). Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry 161:242-248. (Pubitemid 38419274)
87. 3H]amphetamine with rat brain synaptosomes. II. Active transport. J Pharmacol Exp Therap 257:830-835.
88. 3H]amphetamine with rat brain synaptosomes. I. Saturable sequestration. J Pharmacol Exp Therap 257:820-829.